AcelRx Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview
Reuters
Aug 09, 2023
* AcelRx Pharmaceuticals Inc is expected to show a fall in quarterly revenue when it reports results on August 10.
* The Hayward California-based company is expected to report a 86.8% decrease in revenue to $75 thousand from $570 thousand a year ago, according to the estimate from one analyst, based on Refinitiv data.
* Refinitiv's mean analyst estimate for AcelRx Pharmaceuticals Inc is for a loss of 53 cents per share.
* The one available analyst rating on the shares is "hold".
* The mean earnings estimate of analysts was unchanged in the last three months.
This summary was machine generated August 9 at 02:05 GMT. All figures in US dollars unless otherwise stated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.